There is no commercial support for this activity.

About these speakers

Erika Nurmi, MD, PhD received her MD/PhD from Vanderbilt University and her clinical training in adult, child and adolescent psychiatry from UCLA. She is currently Associate Professor of Psychiatry and Biobehavioral Sciences in the UCLA Division of Child and Adolescent Psychiatry. In both research and clinical practice, Dr. Nurmi specializes in obsessive-compulsive and tic disorders. She is Medical Director of the Pediatric OCD Intensive Outpatient Program, a part of the UCLA Childhood OCD, Anxiety, and Tic Disorders Program. At the Greater Los Angeles VA, partner to UCLA, she is the Anxiety Disorders Section Chief. Dr. Nurmi directs a molecular and computational genetics laboratory, investigating genetic contributions to mental illness vulnerability and response to treatment. She is an executive member of the OCD/Tourette Working Group of the Psychiatric Genomics Consortium and UCLA site Principal Investigator for the International OCD ENIGMA Consortium. Dr. Nurmi is a national and international speaker in educational forums, clinician trainings, parent/patient support groups and public events, where she enjoys sharing her passion for science and medicine.

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she has with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.

Erika Nurmi, MD, PhD, reports that she is on the Medical Advisory Board of the Tourette Association of America & Teva Pharmaceuticals and Scientific Advisory Board of Myriad Genetics. She will discuss genetic testing to inform prescribing, and off label uses of augmentation drugs & new alternatives not FDA-approved for OCD but well-supported by literature, in this presentation. This presentation was initially planned and recorded prior to January 1, 2023; therefore, the financial disclosure statement from the speaker reflects only the preceding 12 months, as was the standard at the time. This enduring activity was last reviewed for content validity on June 5, 2024. All conflicts have been mitigated through review.

Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months: Jon Hershfield, MFT, Todd Peters, MD, Elizabeth Ryznar, MD, MSc, Louis Marino, MD, Devi Bhuyan, PsyD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Stacey Garnett, RN, MSN, Stephanie M. Robinson, MSN, RN, PMH-BC, NPD-BC, NE-BC , Heather Billings, RN, Lisa Illum, MLIS, MEd, and Jennifer Tornabene.